TY - JOUR AU - Croce, C. M. PY - 2008 DA - 2008// TI - Oncogenes and cancer JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMra072367 DO - 10.1056/NEJMra072367 ID - Croce2008 ER - TY - JOUR AU - Davies, H. AU - Bignell, G. R. AU - Cox, C. AU - Stephens, P. AU - Edkins, S. AU - Clegg, S. AU - Teague, J. AU - Woffendin, H. AU - Garnett, M. J. AU - Bottomley, W. PY - 2002 DA - 2002// TI - Mutations of the BRAF gene in human cancer JO - Nature VL - 417 UR - https://doi.org/10.1038/nature00766 DO - 10.1038/nature00766 ID - Davies2002 ER - TY - JOUR AU - Press, M. F. AU - Bernstein, L. AU - Thomas, P. A. AU - Meisner, L. F. AU - Zhou, J. Y. AU - Ma, Y. AU - Hung, G. AU - Robinson, R. A. AU - Harris, C. AU - El-Naggar, A. PY - 1997 DA - 1997// TI - HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas JO - J Clin Oncol VL - 15 UR - https://doi.org/10.1200/JCO.1997.15.8.2894 DO - 10.1200/JCO.1997.15.8.2894 ID - Press1997 ER - TY - STD TI - Abbaspour Babaei M, Kamalidehghan B, Saleem M, Huri HZ, Ahmadipour F. Receptor tyrosine kinase (c-kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther. 2016;10:2443–59. ID - ref4 ER - TY - JOUR AU - Wozniak, A. AU - Rutkowski, P. AU - Piskorz, A. AU - Ciwoniuk, M. AU - Osuch, C. AU - Bylina, E. AU - Sygut, J. AU - Chosia, M. AU - Rys, J. AU - Urbanczyk, K. PY - 2012 DA - 2012// TI - Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): polish clinical GIST registry experience JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mdr127 DO - 10.1093/annonc/mdr127 ID - Wozniak2012 ER - TY - JOUR AU - Romei, C. AU - Ciampi, R. AU - Elisei, R. PY - 2016 DA - 2016// TI - A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma JO - Nat Rev Endocrinol VL - 12 UR - https://doi.org/10.1038/nrendo.2016.11 DO - 10.1038/nrendo.2016.11 ID - Romei2016 ER - TY - STD TI - Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014;7:52 ID - ref7 ER - TY - JOUR AU - Hammer, A. M. AU - Sizemore, G. M. AU - Shukla, V. C. AU - Avendano, A. AU - Sizemore, S. T. AU - Chang, J. J. AU - Kladney, R. D. AU - Cuitino, M. C. AU - Thies, K. A. AU - Verfurth, Q. PY - 2017 DA - 2017// TI - Stromal PDGFR-alpha activation enhances matrix stiffness, impedes mammary ductal development, and accelerates tumor growth JO - Neoplasia VL - 19 UR - https://doi.org/10.1016/j.neo.2017.04.004 DO - 10.1016/j.neo.2017.04.004 ID - Hammer2017 ER - TY - JOUR AU - Adams, R. H. PY - 2007 DA - 2007// TI - Investigation of the angiogenic programme with tissue-specific and inducible genetic approaches in mice JO - Novartis Found Symp VL - 283 UR - https://doi.org/10.1002/9780470319413.ch13 DO - 10.1002/9780470319413.ch13 ID - Adams2007 ER - TY - JOUR AU - Passam, F. H. AU - Alexandrakis, M. G. AU - Kafousi, M. AU - Fotinou, M. AU - Darivianaki, K. AU - Tsirakis, G. AU - Roussou, P. A. AU - Stathopoulos, E. N. AU - Siafakas, N. M. PY - 2009 DA - 2009// TI - Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma JO - Pathol Res Pract VL - 205 UR - https://doi.org/10.1016/j.prp.2008.07.007 DO - 10.1016/j.prp.2008.07.007 ID - Passam2009 ER - TY - JOUR AU - Barnhill, R. L. AU - Xiao, M. AU - Graves, D. AU - Antoniades, H. N. PY - 1996 DA - 1996// TI - Expression of platelet-derived growth factor (PDGF)-a, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo JO - Br J Dermatol VL - 135 UR - https://doi.org/10.1046/j.1365-2133.1996.d01-1092.x DO - 10.1046/j.1365-2133.1996.d01-1092.x ID - Barnhill1996 ER - TY - JOUR AU - Beaudry, P. AU - Nilsson, M. AU - Rioth, M. AU - Prox, D. AU - Poon, D. AU - Xu, L. AU - Zweidler-Mckay, P. AU - Ryan, A. AU - Folkman, J. AU - Ryeom, S. PY - 2008 DA - 2008// TI - Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-07-0568 DO - 10.1158/1535-7163.MCT-07-0568 ID - Beaudry2008 ER - TY - STD TI - Aveic S, Tonini GP. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy? Cancer Cell Int. 2016;16:62 ID - ref13 ER - TY - STD TI - Jeong W, Doroshow JH, Kummar S. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer. 2013;37(3):110–44. ID - ref14 ER - TY - JOUR AU - Debiec-Rychter, M. AU - Dumez, H. AU - Judson, I. AU - Wasag, B. AU - Verweij, J. AU - Brown, M. AU - Dimitrijevic, S. AU - Sciot, R. AU - Stul, M. AU - Vranck, H. PY - 2004 DA - 2004// TI - Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC soft tissue and bone sarcoma group JO - Eur J Cancer VL - 40 UR - https://doi.org/10.1016/j.ejca.2003.11.025 DO - 10.1016/j.ejca.2003.11.025 ID - Debiec-Rychter2004 ER - TY - JOUR AU - Wardelmann, E. AU - Merkelbach-Bruse, S. AU - Pauls, K. AU - Thomas, N. AU - Schildhaus, H. U. AU - Heinicke, T. AU - Speidel, N. AU - Pietsch, T. AU - Buettner, R. AU - Pink, D. PY - 2006 DA - 2006// TI - Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-1211 DO - 10.1158/1078-0432.CCR-05-1211 ID - Wardelmann2006 ER - TY - JOUR AU - Hatcher, J. M. AU - Weisberg, E. AU - Sim, T. AU - Stone, R. M. AU - Liu, S. AU - Griffin, J. D. AU - Gray, N. S. PY - 2016 DA - 2016// TI - Discovery of a highly potent and selective Indenoindolone type 1 Pan-FLT3 inhibitor JO - ACS Med Chem Lett VL - 7 UR - https://doi.org/10.1021/acsmedchemlett.5b00498 DO - 10.1021/acsmedchemlett.5b00498 ID - Hatcher2016 ER - TY - JOUR AU - Zarrinkar, P. P. AU - Gunawardane, R. N. AU - Cramer, M. D. AU - Gardner, M. F. AU - Brigham, D. AU - Belli, B. AU - Karaman, M. W. AU - Pratz, K. W. AU - Pallares, G. AU - Chao, Q. PY - 2009 DA - 2009// TI - AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-05-222034 DO - 10.1182/blood-2009-05-222034 ID - Zarrinkar2009 ER - TY - JOUR AU - Altman, J. K. AU - Foran, J. M. AU - Pratz, K. W. AU - Trone, D. AU - Cortes, J. E. AU - Tallman, M. S. PY - 2018 DA - 2018// TI - Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia JO - Am J Hematol VL - 93 UR - https://doi.org/10.1002/ajh.24974 DO - 10.1002/ajh.24974 ID - Altman2018 ER - TY - JOUR AU - Cooper, T. M. AU - Cassar, J. AU - Eckroth, E. AU - Malvar, J. AU - Sposto, R. AU - Gaynon, P. AU - Chang, B. H. AU - Gore, L. AU - August, K. AU - Pollard, J. A. PY - 2016 DA - 2016// TI - A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in Childhood Leukemia & Lymphoma (TACL) study JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1998 DO - 10.1158/1078-0432.CCR-15-1998 ID - Cooper2016 ER - TY - JOUR AU - Sandmaier, B. M. AU - Khaled, S. AU - Oran, B. AU - Gammon, G. AU - Trone, D. AU - Frankfurt, O. PY - 2018 DA - 2018// TI - Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant JO - Am J Hematol VL - 93 UR - https://doi.org/10.1002/ajh.24959 DO - 10.1002/ajh.24959 ID - Sandmaier2018 ER - TY - JOUR AU - Sanga, M. AU - James, J. AU - Marini, J. AU - Gammon, G. AU - Hale, C. AU - Li, J. PY - 2017 DA - 2017// TI - An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia JO - Xenobiotica VL - 47 UR - https://doi.org/10.1080/00498254.2016.1217100 DO - 10.1080/00498254.2016.1217100 ID - Sanga2017 ER - TY - JOUR AU - Cortes, J. E. AU - Kantarjian, H. AU - Foran, J. M. AU - Ghirdaladze, D. AU - Zodelava, M. AU - Borthakur, G. AU - Gammon, G. AU - Trone, D. AU - Armstrong, R. C. AU - James, J. PY - 2013 DA - 2013// TI - Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.48.8783 DO - 10.1200/JCO.2013.48.8783 ID - Cortes2013 ER - TY - JOUR AU - Cortes, J. E. AU - Perl, A. E. AU - Dombret, H. AU - Dohner, H. AU - Steffen, B. AU - Rousselot, P. H. AU - Martinelli, G. AU - Estey, E. AU - Shah, N. P. AU - Burnett, A. K. PY - 2013 DA - 2013// TI - Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant JO - J Clin Oncol VL - 31 ID - Cortes2013 ER - TY - JOUR AU - Martinelli, G. AU - Perl, A. E. AU - Dombret, H. AU - Kayser, S. AU - Steffen, B. AU - Rousselot, P. H. AU - Estey, E. AU - Burnett, A. K. AU - Shah, N. P. AU - Gammon, G. PY - 2013 DA - 2013// TI - Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia JO - J Clin Oncol VL - 31 ID - Martinelli2013 ER - TY - STD TI - Levis MJ, Cortes JE, Gammon GM, Trone D, Kang DR, Li J. Laboratory and clinical investigations to identify the optimal dosing strategy for quizartinib (AC220) monotherapy in FLT3-Itd-positive (+) relapsed/refractory (R/R) acute myeloid leukemia (AML). Blood. 2016;128(22):4042 ID - ref26 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. AU - Wanders, J. AU - Kaplan, R. S. AU - Rubinstein, L. AU - Verweij, J. AU - Van Glabbeke, M. AU - van Oosterom, A. T. AU - Christian, M. C. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.3.205 DO - 10.1093/jnci/92.3.205 ID - Therasse2000 ER - TY - STD TI - NCT02039726. https://clinicaltrials.gov/ct2/show/NCT02039726?term=QuANTUM-R&rank=1. Accessed 11 Oct 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02039726?term=QuANTUM-R&rank=1 ID - ref28 ER - TY - JOUR AU - Joensuu, H. AU - Blay, J. Y. AU - Comandone, A. AU - Martin-Broto, J. AU - Fumagalli, E. AU - Grignani, G. AU - Del Muro, X. G. AU - Adenis, A. AU - Valverde, C. AU - Pousa, A. L. PY - 2017 DA - 2017// TI - Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib JO - Br J Cancer VL - 117 UR - https://doi.org/10.1038/bjc.2017.290 DO - 10.1038/bjc.2017.290 ID - Joensuu2017 ER -